GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial

被引：0

作者：

Shen, Lin ^{[1
]}

Gong, Jifang ^{[1
]}

Song, Yuqin ^{[2
]}

Ye, Dingwei ^{[3
]}

Lu, Zhihao ^{[1
]}

Wang, Siyang ^{[4
]}

Peng, Peijian ^{[4
]}

Chen, Jianhua ^{[5
]}

Jiang, Ou ^{[6
]}

Zhang, Guojun ^{[7
]}

Bai, Yuxian ^{[8
]}

Pan, Jianji ^{[9
]}

Ma, Chunguang ^{[3
]}

Chen, Li ^{[10
]}

Ba, Yi ^{[11
]}

Li, Qi ^{[12
]}

Lu, Ping ^{[13
]}

Zhang, Lingli ^{[14
]}

Yin, Xianli ^{[15
]}

Gu, Shanzhi ^{[15
]}

Zhang, Huilai ^{[16
]}

Su, Hang ^{[17
]}

Jiang, Yongsheng ^{[18
,19
]}

Cao, Bangwei ^{[20
]}

Han, Weiqing ^{[15
]}

Sun, Yan ^{[21
]}

Zhang, Feng ^{[22
]}

Ouyang, Weiwei ^{[23
]}

Dong, Haiying ^{[24
]}

Guo, Jianming ^{[25
]}

Guo, Yabing ^{[26
]}

Xu, Chongyuan ^{[26
]}

Qi, Junyuan ^{[27
]}

Wang, Li ^{[28
]}

Lv, Jun ^{[29
]}

Wang, Xiang ^{[12
]}

Chen, Chris ^{[30
]}

Li, Jing ^{[30
]}

Zheng, Yong ^{[30
]}

Jin, Ge ^{[31
]}

Yang, Yining ^{[31
]}

Zhao, Guodong ^{[31
]}

Yang, Fan ^{[32
]}

Xu, Kehui ^{[32
]}

Liang, Xiangying ^{[32
]}

Pan, Zhaoyang ^{[32
]}

Meng, Haijin ^{[32
]}

机构：

[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[2] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[3] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Urol, Shanghai, Peoples R China

[4] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China

[5] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Thorac Med Dept 1, Changsha, Peoples R China

[6] Second Gen Hosp Neijiang City, Neijiang, Peoples R China

[7] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[8] Harbin Med Univ, Canc Hosp, Haerbin, Peoples R China

[9] Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[10] Nanchang Univ, Affiliated Hosp 5, Nanchang, Jiangxi, Peoples R China

[11] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[12] Shanghai Gen Hosp, Shanghai, Peoples R China

[13] Xinxiang Med Sch, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China

[14] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[15] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China

[16] Tianjin Med Univ Canc Inst & Hosp, Lymphoma Dept, Tianjin, Peoples R China

[17] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China

[18] Huazhong Univ Sci & Technol, Tongji Hosp, Wuhan, Peoples R China

[19] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan, Peoples R China

[20] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[21] Peking Univ Canc Hosp & Inst, Dept Oncol Radiotherapy, Beijing, Peoples R China

[22] Bengbu Med Sch, Affiliated Hosp 1, Bengbu, Peoples R China

[23] Guizhou Canc Hosp, Guiyang, Peoples R China

[24] Zhengjiang Prov Peoples Hosp, Hangzhou Med Coll, Peoples Hosp, Hangzhou, Peoples R China

[25] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[26] Nanfang Hosp, Southern Med Sch, Affiliated Hosp 1, Guangzhou, Peoples R China

[27] Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[28] Jiangsu Prov Hosp, Nanjing, Peoples R China

[29] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[30] WuXi Biol Shanghai Co Ltd, Shanghai, Peoples R China

[31] GloriousMed Technol Co Ltd, Beijing, Peoples R China

[32] Guangzhou Gloria Biosci Co Ltd, Beijing, Peoples R China

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-3275

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3275

引用

页数：4

共 50 条

[41] JS']JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial
Bian, Li
Zhang, Huiqiang
Wang, Tao
Zhang, Shaohua
Song, Haifeng
Xu, Mingli
Yao, Sheng
Jiang, Zefei
ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (18)
[42] Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
Meniawy, T.
Richardson, G.
Townsend, A.
Desai, J.
Gan, H.
Friedlander, M.
Horvath, L.
Jameson, M. B.
Sandhu, S.
Wu, Z.
Qin, Z.
Kang, K.
Markman, B.
ANNALS OF ONCOLOGY, 2017, 28
[43] A phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas
Shen, L.
Li, J.
Xu, N.
Xing, B.
Zhang, Q.
Zhao, Y.
Cao, J.
Ding, J.
Wang, J.
Wang, Y.
Dai, H.
ANNALS OF ONCOLOGY, 2019, 30 : 516 - 516
[44] Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity
Le Tourneau, Christophe
Hoimes, Christopher J.
Zarwan, Corrine
Wong, Deborah Jean Lee
Bauer, Sebastian
Wermke, Martin
Claus, Rainer
Chin, Kevin M.
von Heydebreck, Anja
Cuillerot, Jean-Marie
Gulley, James L.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[45] A PHASE II CLINICAL TRIAL OF IMMUNOTHERAPY WITH ANTI-PD-1 ANTIBODY (NIVOLUMAB) IN ADVANCED/RELAPSED, PLATINUM-RESISTANT OVARIAN CANCER
Hamanishi, J.
Mandai, M.
Matsumura, N.
Abiko, K.
Baba, T.
Yamaguchi, K.
Ueda, M.
Horikawa, N.
Murakami, R.
Koshiyama, M.
Konishi, I.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 400 - 401
[46] Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC)
Yen Chia-Jui
Benjamin, Markman
Chao Yee
Andrew, Hill
Kang Jinyu
Wang Lai
Li Kang
Qi Qinzhou
Wu Zhong
Gan Hui
ANNALS OF ONCOLOGY, 2017, 28
[47] Phase I/II clinical trial of combination of anti-PD-1 mAb, nivolumab with radiotherapy for unresectable and recurrent gastric cancer who failed to standard chemotherapy
Kono, K.
Mimura, K.
Ogata, T.
Yoshimoto, Y.
Yoshida, D.
Nakajima, S.
Sato, H.
Machida, N.
Yamada, T.
Watanabe, Y.
Tamaki, T.
Fujikawa, H.
Inokuchi, Y.
Onozawa, H.
Hayase, S.
Hanayama, H.
Saze, Z.
Katoh, H.
Oshima, T.
Suzuki, Y.
ANNALS OF ONCOLOGY, 2021, 32 : S1053 - S1054
[48] A phase Ib trial of neoadjuvant oncolytic virus OrienX010 (ori) and anti-PD-1 toripalimab (tori) combo in patients (pts) with resectable stage IIIb-IV (M1a) acral melanoma
Wei, X.
Wang, X.
Bai, X.
Li, C.
Mao, L.
Chi, Z.
Lian, B.
Bixia, T.
Kong, Y.
Dai, J.
Andtbacka, R. H. I.
Guo, J.
Cui, C-L.
Si, L.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S907 - S907
[49] Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors (vol 27, pg 3620, 2021)
Curigliano, Giuseppe
Curigliano, Hans
Mach, Nicolas
Doi, Toshihiko
Tai, David
Forde, Patrick M.
Sarantopoulos, John
Bedard, Philippe L.
Lin, Chia-Chi
Hodi, F. Stephen
Wilgenhof, Sofie
Santoro, Armando
Sabatos-Peyton, Catherine A.
Longmire, Tyler A.
Xyrafas, Alexandros
Sun, Haiying
Gutzwiller, Sabine
Manenti, Luigi
Naing, Aung
CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3957 - 3957
[50] A phase 1b clinical trial of anti-PD-1 ab (Toripalimab) plus intralesional injection of OrienX010 in stage melanoma with liver metastases.
Guo, Jun
Cui, Chuanliang
Wang, Xuan
Lian, Bin
Yin, Shanshan
Cong, Yue
Chi, Zhihong
Si, Lu
Sheng, Xinan
Tang, Bixia
Mao, Lili
Bai, Xue
Yan, Xieqiao
Li, Siming
Zhou, Li
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →